Last updated on September 2018

Tysabri Observational Program

Brief description of study

The primary objective of this study is to assess the long-term safety and impact on disease activity and progression of natalizumab in participants with relapsing remitting multiple sclerosis (RRMS) in a clinical practice setting.

Detailed Study Description

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 10 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use, and the impact of treatment on disability in particular by comparing the results with prospectively determined controls from established databases.

Clinical Study Identifier: NCT00493298

Contact Investigators or Research Sites near you

Start Over

US Biogen Clinical Trial Center

Research site
Stoke on Trent, United Kingdom
  Connect »